Hexarelin is a man-made peptide made in a lab. Hexarelin's main job is to turn on a switch on pituitary cells. Hexarelin also tends to raise other body chemicals, like prolactin and a stress hormone called cortisol, which can muddy results and may cause side effects.
Hexarelin is a synthetic hexapeptide growth hormone releasing peptide (GHRP) and ghrelin-receptor (GHSR-1a) agonist that potently stimulates pituitary GH release. It also exerts direct cardioprotective effects via cardiac receptor subtypes (including CD36) that are independent of GH. It is not FDA-approved.
Benefits
The benefits people report — backed by research.
You just read the research on Hexarelin. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Hexarelin is a synthetic hexapeptide growth hormone releasing peptide (GHRP) and ghrelin-receptor (GHSR-1a) agonist that potently stimulates pituitary GH release. It also exerts direct cardioprotective effects via cardiac receptor subtypes (including CD36) that are independent of GH. It is not FDA-approved.
Evidence
Every claim above traces back to a source you can check — here are 4 of them.
Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.
Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro
Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat
Timeline
Key moments in Hexarelin’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions Hexarelin.
FDA's Dallas district office inspected Revive Rx LLC (Houston, TX) between January 27 and February 7, 2025 and issued a Form 483 citing sterile-failure observations — products exposed to sub-ISO 5 air and microbial contamination (mold and spore-forming bacteria) in production areas. The 483's product list includes Hexarelin 6 mg per Vial for Injection among the drugs the compounding pharmacy produced, alongside sermorelin and tesamorelin. The document is inspectional observations, not a final agency determination.
FDA warned API supplier Darmerica, LLC (Davie, FL) after a March 2025 inspection found CGMP failures that render its drug APIs adulterated, plus misbranding violations including distribution of APIs ineligible for 503A compounding. The letter specifically cites the firm's drug listing for Hexarelin Acetate (NDC 71052-621), which reported an incorrect active peptide ingredient. It ties the misbranding to products distributed for compounding use.
Wondering how Hexarelin pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.